Advice +Action for Transformational Growth
To help you create competitive
advantage through superior strategy,
corporate development and product
To deliver compelling ideas &
opportunities. To advise & to act.
The impact will not have escaped your
business; the rules of growth are being
rewritten and either you are being proactive or
you are being left behind.
To stand still and wait will quickly be realised
as a crushing mistake.
Are you confident of success around the next
BackgroundOur industry is changing
The simple linear model of blockbuster Big Pharma pipelines and
guaranteed profit from generic copies is over. As every major ethical
pharma company scrambles to reinvent itself, so must every other
company in the healthcare sector.
The status quo is that there is no status quo.
Changing needsNewstrategies arerequired
Everything needs to given consideration in light of the new reality:
Portfolio, Value Chain, Business Models, Geography, Acquisitions, Divestments, Financing, Partnerships… the lot.
Now is the time to get ahead of the competition, build a future-ready business and deliver better value to stakeholders.
Plan to changeRe-evaluate,Re-create,Re-invest
There are immediate
opportunities to begin the
transformation. Ideas to build
upon. People ready to talk.
It doesn’t need to be a dramatic,
shareholder scaring, customer
alienating step; progress can be
made in small steps.
Start nowTomorrow is not going tobelike today
Start with a strategy for:
- High tech niche-busters
- Branded generics & specialty products
- Consumer healthcare
- Emerging market revenue
- Biotech & diagnostics
Highly experiencedbiotech executive
From 2002 until 2009, Ed was the CFO of Mylan Inc (Pittsburgh, PA), the Top 3 generic pharma giant. He
was instrumental in leading the company through its most dramatic growth phase; transforming it from
a $900million domestic player to a $5.5billion global leader operating in 60 countries.
Most recently Ed was CFO of Convatec, a $17billion private equity owned wound care and hospital
products company. Ed oversaw a short term project that enhanced revenues by 7% and EBITDA by 25%.
During his tenure, he lead the $321million acquisition of the companies first direct-to-patient business; a
Ed was previously CFO of Carefusion Corporation, a newly created entity spun off from Cardinal Health.
Ed oversaw the unification of diverse business units into a $3.5billion corporation, securing initial
financing and leading the successful IPO.
Highly accomplished CFO
Ed successfully led several key financial transactions for Mylan, including a $7.8 billion financing of
Mylan’s acquisition of Merck Generics in May 2007, which was completed in October 2007.
Accomplished with the issuance of nearly $3.0 billion of equity (comprised of $2.1 billion of mandatory
convertible preferred shares and $750.0 million of common stock) and the syndication of over $4.0
billion of bank debt both in the U.S. and Europe in the middle of one of the worst credit markets in
Until the end of 2013 Peter led Qualitest Pharmaceuticals, the Generic Drug Division of Endo. Oversaw all
Commercial Operations, Research and Development, Manufacturing and Supply Chain. Restructured
R&D Organization. Oversaw 14% year to year growth. Drove key M&A programs. Qualitest is the 5th
largest Generic Company in the US as measured by number of Prescriptions with Facilities in Huntsville,
Alabama and Charlotte, North Carolina.
Previously Peter lead Patheon’s Commercial Operations in North America including 5 Manufacturing
sites. Serving as CEO during leadership transition. Oversaw significant improvement in Manufacturing
Operations, increased profitability and grew Pharmaceutical Development Business; with $700 million in
Revenue and 4700 employees.
Prior to joining Patheon, Peter spent 14 years with Wyeth Pharmaceuticals. From 2003 to 2009 he was
responsible for supply of Wyeth’s Consumer Healthcare products globally; consisting of six
manufacturing sites and well known brands as Advil, Centrum Vitamins, Chapstick and Robitussin. From
1995 to 2003 he served in a variety of senior Engineering and Operations roles for the Prescription Drug
side of the Wyeth business.
He has a BS in Mechanical Engineering from Villanova University and an MBA from Philadelphia
Peter took control of both Qualitest and Patheon during times of change; guiding them through major
restructuring and onto firm foundations for growth.
Asa is the Founder & CEO of Generic Pharma 2.0; a leading strategic consultancy utilising a worldwide
network of 30,000 companies, developed over 17 years in the industry.
Generic Pharma 2.0 is founded on the expertise Asa has developed through hundreds of client projects;
dedicating itself to helping companies grow through business development and marketing. Its industry
leading network provides GP20 with a unique level of market intelligence and insight; used to provide
strategic consulting to leading global players.
The company has operations in over a dozen countries; with highly experienced and well connected local
experts providing clients with decision making data. It counts all the major generic companies and many
‘big pharma’ organisations as clients. Asa personally consults on strategic portfolio selection and
optimisation; presenting at conferences around the world. He is also a thought leader on the future of
the generic industry.
Asa is a Director of Medical Brands BV, a market leading consumer healthcare devices company.
Globally connected product expert
Prior to founding GP20, Asa launched genericlicensing.com, the industries first database of licensing
assets. Growing it from 500 products to over 9000; it is used by over 2000 licensing teams worldwide
and counts all major pharma companies as clients.
Aziz had a pivotal role in the European expansion of Arrow Group, from its inception in 2001 to the 2009
$1.75billion acquisition by Watson Pharmaceuticals (now Actavis).
As Head of Business Development at Arrow, Aziz reported directly to the CEO and was responsible for all
multi-country licensing deals and corporate development; with special focus on entering new markets.
He implemented aGroup strategy into newly established affiliates based on a new sales plan and
Prior to Arrow, Aziz was Business Development, API and Patent manager for Merck Generiques (now part
of Mylan Inc) in France. He was responsible for sourcing, European licensing of injectables and patent
strategy for the French market.
Aziz was responsible for the expansion of the EU sales structure, creation of affiliates as a startup or
through Joint Ventures.
He was a Board Director of several affiliates: appointing top level management, strategy, financial,
budgeting, hands-on P&L management, business development and sales force planning. Actively
involved in portfolio management of the concerned affiliates, forecasting products income for new
Dr. Berman has over 12 years of entrepreneurial and industry experience working at the interplay of
science and business. His experience offers him a unique combination of business acumen and scientific
credibility with the ability to assess, quantify, and bridge both disciplines.
He began his career at MD Anderson Cancer Center in the technology transfer division where he was
responsible for assessing the market, patent, and scientific merits of numerous oncology based
technology platforms in order to ascertain their commercial viability.
At Eli Lilly, Dr. Berman was responsible for facilitating collaborations between Eli Lilly and key opinion
leaders for marketed and pipeline compounds including Gemzar (Gemcitabine), Pemetrexed (Alimta),
Erbitux (Cetuximab) & Ramicurumab.
Prior to Lilly, Dr. Berman served as regional scientific director at Novartis Pharmaceuticals where he
served as the scientific point of contact between Novartis and key opinion leaders for development and
initiation of collaborations, clinical trials, and investigator initiated trials.
Dr Howard Berman
Highly experiencedbiotech executive
Dr. Berman has enjoyed much success as an entrepreneur and as a consultant. Dr. Berman currently
serves as Managing Director at Notre Capital, based in Houston, responsible for biopharmaceutical
investment analysis. Dr. Berman serves as advisor to Cingulate Therapeutics, 20/20 Gene Biosystems,
Companion Dx, Immune Cell Therapy, Inc. and United Pharmaceuticals.
Dr. Berman received his Masters and Ph.D. in Medical Pharmacology from Weill Medical College of
Tony has been actively involved in the Chinese chemical and pharmaceutical industries for over 20 years.
His primary focus is in the development and leadership of multicultural teams consisting of Western and
Chinese professionals. At Eastar Chemicals Corporation, he started as Sales and Marketing Manager,
working his up to eventually take on the role as President and board member. Tony led Eastar’s growth
from a trading company to a respected partner to both global pharma companies and leading Chinese
Tony is also the CEO of Eastar Industries LLC where the focus is in bringing innovative pharmaceuticals
and medical devices from small and medium size North American and European companies to China and
South East Asia.
In addition to Eastar, Tony is a seasoned entrepreneur. He invests and is instrumental in building a
number of start-up businesses.
Tony grew up in California, USA but is fluent in both Mandarin and Cantonese Chinese.
China commercialization expert
Dr. Vladimir Krasnikov is the acknowledged leader of the Russian pharmaceutical market. He was
awarded the European Awards Diploma for Achievements in Health Development in Russia and the
Medal for a Merit in the Development of Pharmaceutical Business in Russia.
Vladimir started his business career with Janssen-Cilag, a company of J&J, where he developed the
foundations of Janssen-Cilag in Russia being one of its first employees in Russia in the early 1990’s. Then,
he continued his career path with Roche, GE Medical Systems, Glenmark Pharmaceuticals with proven
strategic sales and marketing management experience.
As a top manager at multinational companies, he successfully launched both Rx and OTC products and
developed a business platform for companies' operations in Russia and ex-USSR countries (Ukraine,
Kazakhstan and Byelorussia).
In 2004 he set up the Russian Pharmalicensing Group, specialising in market research and business
development services. Vladimir is now the leading market access expert, connected at the highest levels
of the Russian pharma industry.
Dr Vladimir Krashnikov
Russia’s leading marketaccess expert
Stu focuses on the global generics practice, working closely with many different practice
areas across the firm, including litigation, intellectual property, antitrust, FDA/regulatory,
corporate, and mergers and acquisitions.
Prior to joining the firm, Stu served as chief legal officer of Mylan Pharmaceuticals, one of
the world's leading generic and specialty pharmaceutical companies. In this position, Stu
reported directly to the chief executive officer and handled all legal issues affecting both
the parent company and its subsidiaries.
Wilson Sonsini Goodrich & Rosati have unrivalled experience and success in both high-tech and generic pharma.
Dr. Jeffrey Guise practices in the area of intellectual property law and has extensive
experience in all aspects of intellectual property acquisition, licensing, and enforcement.
Jeff's intellectual property litigation experience includes pre-trial and trial experience,
interference proceedings, and litigation counseling. Jeff's patent prosecution experience
includes drafting and prosecuting U.S. and international patent applications for a wide
range of biotechnology, pharmaceutical, immunology, medical diagnostics, genetic
engineering, agricultural biotechnology, genomics, proteomics clients, bioinformatics
software, and electronic hardware systems.
Partner,Patent Litigation Generics
Whilst we do offer pure strategic advice
like the big guys, we don’t leave it with
you and walk away; we have the
experience and connections to turn the
plan into reality. We stimulate thinking,
we guide action, we take responsibility.
We are accountable.
Our vastly experienced team will stimulate, guide and contribute to the crafting of future-proof corporate strategies
that will bring growth. Whilst we might not have a vast team of MBA graduates to research and analyze even
minutiae of a planning document, we do however have decades of hands-on experience to provide priceless insights.
We believe reality is more influential than theory. We integrate operational and implementation smarts with a vision
of what will be required to create competitive advantage in the changing industry. Our track record of significant
industry deals helped create the high growth leaders of today, we can help you challenge them tomorrow.
Many transformations require a step change; our team can both readily identify and support the execution of
transactions of any size. We have the rare capability to rapidly evaluate potential transactions from all angles;
financial, legal, operational, portfolio, marketing, people.
Our networks for deal-flow cover all aspects of the industry; API manufacturing, contract manufacturing, formulation
development, marketing & sales. We also have very strong connections to sources of finance in USA, Europe and
In association with Generic Pharma 2.0, TPP has access to the largest global decision-marker network in the industry;
15,000 strong and growing daily. Uncovering opportunities to enhance your business value at home or abroad
through new connections with value-adding companies or products.
The team is experienced in establishing innovative collaboration models that rapidly enhance growth and has helped
license hundreds of products of all types.
TPP believes it can provide all the essential elements for competitive success
Insights Process Talent
Strategy, in order to provide
competitive advantage, requires
unique insights and ideas.
Execution, requires a robust and
well-tried process in order to be
successful. Trust experience.
Designing long term success is determined
by the collective brain power and street
smarts of your team. Is your team ready?
Asa and the team have been an extremely valuable partner with the building of our business. Their
experience in the generic business and wealth of connections have helped us at every step.
“ David Guy, CEO
Oversaw detailed market analysis for all global regulated markets to build the business case for entry by top tier generic player.
Worked with executive team to devise most suitable strategy and undertook due diligence of all acquisitions considered.
Devised the European growth strategy for a new Chinese funded generic company. Integrated into portfolio, alliance and
operational strategy teams. Engaged to operate certain element of technical and regulatory management. Will be first company
to tender in Europe with Chinese manufactured sterile product.
Negotiated minority interest in multiple European distributors in exchange for product portfolio rights. Secured agreement to
convert into acquisition of majority under certain conditions and exited all positions at the transaction event expected.
Pivotal role in global growth of a large US generic company; identifying, engaging and negotiating a wide variety of projects,
many of which were taken through to closure. Main projects included the multi-billion dollar acquisition of a large European
competitor and a major Asian supplier.
Worked with Top 10 pharma company to source, engage and negotiate terms for a range of key products for first launch in 26
countries. Advised the client on deal terms, market intelligence and engagement processes to ensure the quickest decision
making timetable. Project upgraded to involve advice on the clients global generic strategy.
Managed the licensing of over 200 generic products from international sources for multi-territory exploitation to establish and
grow the generic division of a top tier US speciality pharma company. Negotiation of all IP and commercial elements; integrated
with legal, procurement, regulatory and sales teams.
Licensed portfolio of female health products for publicly traded speciality pharma company. Advised on marketing strategy,
established local distribution channels and future product opportunities.
A selection of projects and achievements by the team
Ideas and opportunities are just a phone call or email away
+1705 615 1500
+86 138 1610 7501
+44 (0) 7775 810087
+7 495 22 333 44
Advice +Action for Transformational Growth